MILPAX^® F

Treatment of symptoms of gastro-oesophageal reflux, such as reflux-related regurgitation, heartburn and indigestion, for example after meals, or during pregnancy, or in patients with symptoms related to reflux oesophagitis.

• Alginato de Sodio 500 mg/10ml.
• Bicarbonato de Sodio 267 mg/10ml.
• Carbonato de Calcio 160 mg/10ml.

R.S. N°: EE-08176.

• Bottle x 360 ml. Cherry flavour.
• Envelopes box x 12 sachets. Cherry flavour.

Avoid prolonged use because it increases the risk of developing kidney stones. See other Warnings and precautions in the insert.

The drug contains sorbitol and is therefore not suitable for patients with fructose intolerance.

This medicine is contraindicated in patients with known hypersensitivity to sodium alginate, sodium bicarbonate and calcium carbonate or to any of the excipients. As the product contains sodium it is recommended to restrict salt intake in the diet eg in some cases of congestive heart failure and kidney failure. As the product contains Calcium, care should be taken in treating patients with hypercalcaemia, nephrocalcinosis and recurrent calcium-containing kidney stones. This medicine contains propylparaben and butylparaben which may cause allergic reactions (possibly delayed). The drug contains sorbitol and is therefore not suitable for patients with fructose intolerance.

Effects of the active ingredients on pregnancy and breastfeeding in newborns/infants of treated mothers have not been demonstrated. MILPAX F can be used during pregnancy and lactation.